Use of the drug aleglitazar has shown the ability to lower glucose levels and have favorable effects on cholesterol. It did not reduce the risk of cardiovascular death, heart attack or stroke among patients with type 2 diabetes and recent heart attack or unstable angina, according to a iJAMA/i study released online to coincide with presentation at the 2014 American College of Cardiology Scientific Sessions. Cardiovascular disease remains the dominant ...
Read More
You have just read an article categorized health
titled Medication Does Not Reduce Risk of Recurrent CV Events Among Diabetes Patients.
Written by:
editor -
Sunday, March 30, 2014
There are currently no comments for "Medication Does Not Reduce Risk of Recurrent CV Events Among Diabetes Patients"
Post a Comment